Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; Clathrin heavy chain and formiminotransferase cyclodeaminase

被引:70
作者
Seimiya, Masanori
Tomonaga, Takeshi [1 ]
Matsushita, Kazuyuki
Sunaga, Masahiko
Oh-ishi, Masamichi [2 ]
Kodera, Yoshio [2 ]
Maeda, Tadakazu [2 ]
Takano, Shigetsugu [3 ]
Togawa, Akira [3 ]
Yoshitomi, Hideyuki [3 ]
Otsuka, Masayuki [3 ]
Yamamoto, Masakazu [4 ]
Nakano, Masayuki [5 ]
Miyazaki, Masaru [3 ]
Nomura, Fumio
机构
[1] Chiba Univ, Grad Sch Med, Dept Mol Diagnosis, Chuo Ku, Chiba 2608670, Japan
[2] Kitasato Univ, Sch Sci, Dept Phys, Lab Biomol Dynam, Kanagawa, Japan
[3] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba 2608670, Japan
[4] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo, Japan
[5] Chiba Med Ctr, Natl Hosp Org, Div Clin Invest, Chiba, Japan
关键词
D O I
10.1002/hep.22364
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Early diagnosis of hepatocellular carcinoma (HCC) greatly improves its prognosis. However, the distinction between benign and malignant tumors is often difficult, and novel immunohistochemical markers are necessary. Using agarose two-dimensional fluorescence difference gel electrophoresis, we analyzed HCC tissues from 10 patients. The fluorescence volumes of 48 spots increased and 79 spots decreased in tumor tissues compared with adjacent nontumor tissue, and 83 proteins were identified by mass spectrometry. Immunoblot confirmed that the expression of clathrin heavy chain (CHC) and Ku86 significantly increased, whereas formiminotransferase cyclodeaminase (FTCD), rhodanese, and vinculin decreased in tumor. The protein expression in tumor and nontumor tissues was further evaluated by immunostaining. Interestingly, CHC and FTCD expression was strikingly different between tumor and nontumor tissues. The sensitivity and specificity of individual markers or a combination for the detection of HCC were 51.8% and 95.6% for CHC, 61.4% and 98.5% for FTCD, and 80.7% and 94.1% for CHC+FTCD, respectively. Strikingly, the sensitivity and specificity increased to 86.7% and 95.6% when glypican-3, another potential biomarker for HCC, was used with FTCD. Moreover, CHC and FTCD were useful to distinguish early HCC from benign tumors such as regenerative nodule or focal nodular hyperplasia, because the sensitivity and specificity of the markers are 41.2% and 77.8% for CHC, 44.4% and 80.0% for FTCD, which is comparable with those of glypican-3 (33.3% and 100%). The sensitivity significantly increased by combination of these markers, 72.2% for CHC+FTCD, and 61.1% for CHC+glypican-3 and FTCD+glypican-3, as 44.4% of glypican-3 negative early HCC were able to be detected by either CHC or FTCD staining. Conclusion: Immunostaining of CHC and FTCD could make substantial contributions to the early diagnosis of HCC.
引用
收藏
页码:519 / 530
页数:12
相关论文
共 50 条
[1]   A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23) [J].
Argani, P ;
Lui, MY ;
Couturier, J ;
Bouvier, R ;
Fournet, JC ;
Ladanyi, M .
ONCOGENE, 2003, 22 (34) :5374-5378
[2]   Structural basis for vinculin activation at sites of cell adhesion [J].
Bakolitsa, C ;
Cohen, DM ;
Bankston, LA ;
Bobkov, AA ;
Cadwell, GW ;
Jennings, L ;
Critchley, DR ;
Craig, SW ;
Liddington, RC .
NATURE, 2004, 430 (6999) :583-586
[3]   58K, a microtubule-binding golgi protein, is a formiminotransferase cyclodeaminase [J].
Bashour, AM ;
Bloom, GS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (31) :19612-19617
[4]  
BLOOM GS, 1989, J BIOL CHEM, V264, P16083
[5]   Structural dynamics of α-actinin-vinculin interactions [J].
Bois, PRJ ;
Borgon, RA ;
Vonrhein, C ;
Izard, T .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (14) :6112-6122
[6]   Primary liver cancer:: Worldwide incidence and trends [J].
Bosch, FX ;
Ribes, J ;
Díaz, M ;
Cléries, R .
GASTROENTEROLOGY, 2004, 127 (05) :S5-S16
[7]   Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor [J].
Bridge, JA ;
Kanamori, M ;
Ma, ZG ;
Pickering, D ;
Hill, DA ;
Lydiatt, W ;
Lui, MY ;
Colleoni, GWB ;
Antonescu, CR ;
Ladanyi, M ;
Morris, SW .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :411-415
[8]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[9]   Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma [J].
Capurro, M ;
Wanless, IR ;
Sherman, M ;
Deboer, G ;
Shi, W ;
Miyoshi, E ;
Filmus, J .
GASTROENTEROLOGY, 2003, 125 (01) :89-97
[10]   ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC) [J].
Chikatsu, N ;
Kojima, H ;
Suzukawa, K ;
Shinagawa, A ;
Nagasawa, T ;
Ozawa, H ;
Yamashita, Y ;
Mori, N .
MODERN PATHOLOGY, 2003, 16 (08) :828-832